The key distinction is renal excretion rather than renal metabolism: lithium is not meaningfully metabolised and is eliminated almost entirely by the kidneys, while paliperidone clearance also depends strongly on renal function SmPC Invega Rijavec & Rijavec B 2026.
- Lithium: the clearest example of a psychotropic dependent on renal elimination; reduced kidney function, dehydration and sodium depletion can cause accumulation and toxicity Rijavec & Rijavec B 2026.
- Paliperidone: an antipsychotic whose clearance falls as renal function declines; total clearance is reduced by approximately 32%, 64% and 71% in mild, moderate and severe renal impairment, respectively SmPC Invega.
- Midazolam — an important metabolite distinction: its active metabolite, alpha-hydroxymidazolam, relies heavily on renal excretion, so renal impairment can affect exposure to active drug metabolites even when the parent medicine is not described as renally metabolised Shimoyama et al. 2026.
Practical implication: check the individual medicine’s BNF entry or SmPC for renal dose adjustments rather than treating renal excretion and metabolism as interchangeable NICE CKS. For lithium, assess renal function, electrolytes and serum lithium concentrations, particularly during intercurrent illness or changes to interacting medicines such as ACE inhibitors, ARBs and diuretics Pilarski et al. 2026.
Key References
- SmPC: Maxolon Tablets 10mg
- SmPC: Invega 3 mg prolonged-release tablets
- SmPC: Invega 6 mg prolonged release tablets
- SmPC: Invega 9 mg prolonged-release tablets
- NICE CKS: Acute kidney injury
- NICE CKS: Bipolar disorder
- NICE CKS: Chronic kidney disease
- NICE CKS: Kidney injury - acute
- (Balant et al., 1983): Consequences of renal insufficiency on the hepatic clearance of some drugs.
- (Rijavec and Rijavec B., 2026): Molecular Mechanisms of Acute Drug Toxicity in Polypharmacy: Analgesic-Psychotropic Interactions.
- (Shimoyama et al., 2026): The Toxic Filter: Chronic Kidney Disease Drives Neuro-Psychiatric Toxicity and Agitation in Sepsis Survivors Aged ≥ 90 Years: A Retrospective Cohort Study Using the National Database of Japan.
- (Pilarski et al., 2026): Psychopharmacological Treatment in Patients with Heart Failure: A Narrative Review of Mood Stabilizers and Antipsychotics.